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POPULÄRVETENSKAPLIG SAMMANFATTNING
Det övergripande syftet med denna avhandling är att undersöka medicinsk beslutsförmåga 
hos geriatriska patienter med och utan demenssjukdom. Hos personer med demenssjukdom 
förekommer ofta en nedsatt förmåga att fatta beslut i medicinska kontexter, orsakad av de 
kognitiva svårigheter som är kärnan i diagnosen.
Äldre personer är en utsatt grupp när det gäller att fatta självständiga beslut i medicinska 
sammanhang. Att uppmärksamma vilka personer som behöver stöd för att kunna fatta egna, 
välgrundade beslut är viktigt för att främja patienters delaktighet, men också för att kunna 
skydda de individer som saknar beslutsförmåga, exempelvis genom att engagera ställföre-
trädare.
Att fatta välgrundade, självständiga, beslut kräver flera olika språk- och tankemässiga 
förmågor: du måste förstå informationen som ligger till grund för beslutet, du behöver väga 
för- och nackdelar mot varandra, och slutligen behöver du uttrycka ditt beslut på ett förståe-
ligt sätt till omvärlden. Beslut inom vården är ofta svårare att fatta än mer vardagliga beslut, 
eftersom informationen som ligger till grund för beslutet ofta innehåller medicinska termer 
som gemene man inte känner till. Informationen är ännu mer komplex när det handlar om att 
delta i en medicinsk forskningsstudie. 
Studierna i avhandlingen innefattar två olika typer av beslutsprocesser:  1) att bestämma 
sig för att delta i en medicinsk forskningsstudie eller inte, och 2) att delta i ett vårdplanerings-
möte på en geriatrisk vårdavdelning. 
I första studien användes metoden Samtalsmatta i ett försök att förbättra kommunikationen 
under vårdplaneringar, men resultaten visade inte på någon förbättring. I andra studien under-
söktes om Språkligt målgruppsanpassad information kunde underlätta ställningstagande till 
att delta i ett forskningsprojekt för patienter som var i ett tidigt skede av Alzheimers sjukdom. 
Den medicinska beslutsförmågan var dock oförändrat låg.  
Tredje studien konstruerade och presenterade egenskaper hos ett nytt test: Kliniskt instrument 
för medicinsk beslutsförmåga. Det är ett snabbt test som indikerar om en patient har nedsatt 
beslutsförmåga att fatta ett välgrundat beslut gällande att delta i medicinska forskningspro-
jekt. Fjärde studien använde sedan detta test för att undersöka hur vanligt det var med ned-
satt medicinsk beslutsförmåga hos inneliggande geriatriska patienter utan demenssjukdom. 
Resultaten visade att en majoritet hade problem att fatta denna typ av beslut. Det är därför 
av intresse att följa upp detta med att undersöka förekomsten av nedsatt medicinsk besluts-
förmåga hos ytterligare patientgrupper.
I slutet av avhandlingen presenteras ett förslag på hur forskare i rekryteringsprocessen av 
deltagare på ett systematiskt sätt kan efterfråga samtycke från en geriatrisk patient. I fortsatt 
forskning vore det intressant att utvärdera om detta flödesschema kan främja ett mer patient-
säkert tillvägagångssätt.
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ABSTRACT
Introduction: Medical decision-making capacity concerns a patient’s cognitive abili-
ties to make autonomous decisions regarding own person in medical contexts such as to 
choose treatment or accept/decline participation in research projects. Cognitive communica- 
tive functions are needed in order to process information, reach a decision and articulate it. 
Communication within medical decision-making processes requires receptive, cognitive 
communicative and expressive language skills. 
The overall aim of the thesis is to investigate medical decision-making capacity using 
communication based approaches to facilitation and assessment in geriatric patients with and 
without dementia. 
Methods: Study I investigated whether participants at discharge planning meetings 
perceived better communication function in geriatric patients with cognitive impairment who 
had been prepared using the Talking mats method. Study II examined if medical decision- 
making capacity improved among patients with Alzheimer’s disease if written participant 
information were presented as linguistically adapted, more readable vignettes. The medi-
cal decision-making capacity was measured by Swedish linguistic instrument for medical 
decision-making. Study III developed a new test to assess medical decision-making capa-
city: Clinical instrument of medical decision-making capacity. The test was validated by 
comparing results between three groups: patients with Alzheimer’s disease, patients with 
Mild cognitive impairment and healthy controls. Test scores were compared to test results 
on designated linguistic and cognitive tests. Study IV used Clinical instrument of medical 
decision-making capacity to investigate the prevalence of impaired medical decision-making 
among geriatric in-patients without known cognitive impairment.
Results: Neither Talking mats nor Adapted vignettes was found to improve geriatric patients’ 
ability to participate in the specified medical decision-making processes. Clinical instru-
ment of medical decision-making capacity showed good test properties. Positive correlations 
were found between preserved medical decision-making capacity and longer formal educa-
tion, well-functioning overall cognition, high premorbid cognitive function, and scores on 
specific tests assessing e. g. comprehension and vocabulary. An unexpected finding was that the 
prevalence of impaired medical decision-making capacity was as high among in-patients 
with somatic conditions as among out-patients in early stage of Alzheimer’s disease. 
Conclusions: Medical decision-making processes are difficult to participate in not only for 
patients with dementia but also for in-patients, regardless of whether a neurodegenerative 
process is present or not. A flow-chart was constructed from a cognitive communicative 
perspective. The purpose was to suggest a standardized way to promote the best possible 
participation and obtain the most accurate perception of the patient’s wishes when asking 
geriatric patients for informed consent.  
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LIST OF ABBREVIATIONS
ACED Assessment of capacity for everyday decisions
AD Alzheimer’s disease
BeSS Test battery of high-level language functions 
CCTI Capacity to consent to treatment interview
CG Control group (patients)
DLS Diagnostic material for analysis of reading and writing skills
HCG Healthy control group
KIMB Clinical instrument of medical decision-making capacity
LIMD Swedish linguistic instrument for medical decision-making
MacCAT-CR MacArthur competence assessment tool for clinical research
MacCAT-T MacArthur competence assessment tool for treatment
MCI Mild cognitive impairment
MDC Medical decision-making capacity
MMSE Mini-mental state examination
MOCA Montreal cognitive assessment
RAVLT Rey auditory verbal learning test
ROC Receiver operating characteristic
SVIT Sentence structure, vocabulary load, idea density, human and 
personal interest
TMG Talking mats group
UBACC University of California brief assessment of capacity to 
consent
VAS Visual analogue scale 
Definitions of phrases
Medical decision-making capacity: The cognitive ability an individual has to make an 
autonomous decision in a medical context.
Medical decision-making process: The process to reach a decision within medical 
contexts, which involves an individual’s capacity but also the situation and the person 
asking for a decision.
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AIMS OF THESIS
The overall aim is to investigate medical decision-making capacity in geriatric 
patients with and without dementia. Communication-based approaches are used to examine 
two methods for facilitation, and assessment of capacity to give informed consent. 
The main aim of each study included is:
• Compare the perceptions of patients, family members, nurses and   
social care workers concerning patients’ communication in discharge 
planning meetings depending on whether geriatric in-patients with 
cognitive impairment are prepared using  Talking mats or not. 
• Investigate whether use of linguistically adapted vignettes yields any 
improvement in medical decision-making capacity among patients 
with Alzheimer’s disease. 
• Develop and validate a written, vignette-based test to detect impaired 
medical decision-making capacity among patients with Alzheimer’s 
disease and Mild cognitive impairment. 
 
• Investigate the prevalence of impaired medical decision-making  
capacity among geriatric in-patients without dementia or acute  
confusion.
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OUTLINE OF THESIS
The background centers around medical decision-making capacity in geriatric patients. 
A communicative base is used to describe and compare different aspects of medical 
decision-making capacity, including patient participation and health literacy. Based on the 
four cognitive components that medical decision-making capacity is described as consisting 
of, tests that assess medical decision-making capacity are outlined together with various 
conditions in the geriatric population which can affect medical decision-making capacity. 
Approaches to support geriatric patients in medical decision-making processes are described. 
The thesis examines medical decision-making from two different aspects: facilitation and 
assessment. The Talking mats method is used in an attempt to support communication and 
participation in discharge planning meetings for patients with dementia or other documented 
cognitive impairment. Adapted vignettes is used for patients with Alzheimer’s disease in an 
attempt to increase medical decision-making capacity regarding giving informed consent. 
The second aspect focuses on assessing medical decision-making capacity. A test called 
Clinical instrument of medical decision-making capacity (KIMB) is constructed and valida-
ted among patients with and without dementia, as well as healthy controls. Finally, KIMB 
is used to examine the prevalence of impaired medical decision-making capacity among 
geriatric in-patients with somatic illnesses. 
The sections Methodological considerations and Integrated results present the included 
studies briefly, highlighting similarities and differences. In the concluding Discussion, the 
ethical dilemma concerning promoting autonomy and need to protect patients who lack 
medical decision-making capacity, is highlighted based on two important conclusions: 
geriatric in-patients are at risk of impaired medical decision-making capacity regardless of 
whether dementia is present or not; and increasing capacity using communicative and/or 
cognitive support may prove difficult. Figure 1 shows a flow-chart of the working process 
for the thesis.
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1 BACKGROUND
1.1 OVERVIEW OF THE GERIATRIC POPULATION
Communication in medical decision-making requires receptive, cognitive communicative 
and expressive language skills. Receptive language skills are fundamental to participation in 
medical decision-making. Understanding information is the first requirement before proces-
sing the information. Cognitive communicative skills are needed to evaluate and apply the 
information to one’s own situation. Expressive language skills are needed to communicate a 
choice, but also in order to give information to health care personnel, for example regarding 
symptoms. In most circumstances, medical decision-making capacity is regarded as a con-
tinuum, not a dichotomous function which either exists or not; different decisions are more 
or less complex and therefore place higher or lower demands on higher cognitive functions.1 
The following conditions are relatively prevalent among geriatric patients and can affect 
communication and ability to participate in medical decision-making processes negatively.2,3
Cognitive communicative disorders (CCD) include all communicative disorders which 
are caused by cognitive impairment, including Mild cognitive impairment, dementia and 
other neurodegenerative disorders.4 From the perspective of CCD, a person’s ability to 
produce and understand speech reflects his/her cognitive capacities. Different parts of the 
brain may be affected by disease, and result in different cognitive symptoms and impairment 
of specific language and communicative abilities.5 Whenever cognitive functions are tempo-
rarily or permanently affected, a warning flag should be raised regarding possible communi-
cation difficulties and impaired medical decision-making capacity.
 
Alzheimer’s disease (AD) is a primary neurodegenerative disease which impairs a person’s 
capacity to manage everyday living activities independently. The disease has an insidious 
onset, and progresses over time. Problems with memory are a core criterion, but other cogni-
tive functions are also affected. Difficulties regarding linguistic abilities include for example 
finding words, understanding and struggling with writing. Communicative skills have been 
highlighted as an important factor in maintaining quality of life and participation in daily 
activities.6 Complex tasks and reasoning are more difficult than concrete tasks for 
patients with AD. Impaired visuospatial abilities are common. Besides cognitive impairment, 
changes in behavior and personality can emerge, such as decreased motivation or increased 
tendency to withdraw socially.7,8
Mild cognitive impairment (MCI) is a condition that is manifested by different cognitive 
symptoms in an individual, but does not fulfil the criteria for dementia. Diagnostic criteria for 
MCI include subjective complaints of declining cognitive functions and impaired cognitive 
functions shown by objective assessment. However, global cognitive function and ability to 
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perform activities of daily living are preserved.9 Patients with MCI are at heightened risk of 
developing AD.10-12 
Multimorbidity in a patient has been defined in different ways, but the two most common are 
two or more chronic conditions present or three or more chronic conditions present. Several 
definitions include age criterion of ≥ 65 years, while others set the limit to 75 years or older. 
The diversity of definitions complicates efforts to compile data on the prevalence and conse-
quences of multimorbidity.13
As for multimorbidity, frailty has been defined and operationalized in several ways.14 Simpli-
fied, frailty describes the degree to which aging has impaired a person’s physical, psycholo-
gical and social function,15 or as an age-related syndrome that affects a patient’s capability to 
manage external stressors.16 Attempts have been made to define subgroups within the other-
wise heterogenic group of patients.17 Frailty increases risk for cognitive impairment, and vice 
versa.14,16,18-22 Since both frailty and cognitive decline are linked to aging, the term cognitive 
frailty have been introduced.14,18 
1.2 MEDICAL DECISION-MAKING CAPACITY
1.2.1	 Definition 
Medical decision-making capacity (MDC) concerns a patient’s cognitive abilities to make 
decisions regarding own person in medical contexts. MDC is a complex cognitive func-
tion, relying on, for example, abilities to: understand information; ponder a future, hypo- 
thetical situation; evaluate different choices; reason regarding risks and benefits; make a 
choice; and communicate it in an intelligible way.23,24 While the terms are sometimes used inter- 
changeably, MDC should not be confounded with medical decision-making competency, 
which regards legal standards and is a juridical status a person can be deprived of within 
the legal system. Co-existing terms for MDC are healthcare consent capacity and health- 
care decision-making capacity.25 Different terms are used to specify what type of decision at 
stake: “capacity to consent to treatment” indicates that the decision takes place within routine 
medical care,26 while “informed consent capacity” and “research consent capacity” signal 
that the decision at hand regards participation in research.27 In this thesis, the term MDC is 
used consistently.
1.2.2	 The	four-component	model 
MDC was originally discussed in ethical and legal terms: an individual must be 
competent to make decisions within medical contexts. At the end of the 20th century, 
researchers agreed to describe MDC according to a cognitive four-component model. 
Focus was on understanding, appreciation, reasoning and expression of a choice, which were 
considered essential parts of a well-founded decision.28,29 All four components must be 
present for a person to be regarded as having a valid MDC. The baseline in the model is 
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to understand the information the decision should be based on. Appreciation means that 
a patient should exhibit the capability to apply the information to his/her own situation. 
The component reason focuses on the person’s ability to compare the risks and benefits of 
different alternatives in a rational and logical way. Finally, a patient should be able to express 
his or her choice in an unambiguous way.26,30 The four-component model is predominant in 
research aiming to find predictors for MDC.25
Studies regarding which cognitive functions contribute to MDC are not conclusive. It has 
been emphasized that MDC relies on multifaceted multi-domain cognitive functions.31,32 
Possible explanations for the diverse research results are that: 1) several definitions of MDC 
exist; 2) the tests used to assess MDC also differ; 3) correlations to MDC have been investi-
gated using extensive neuropsychological test batteries without specific hypotheses,25,33,34 and 
using stepwise regression, which may be an inappropriate basis for making deductions about 
correlations.35  Cognitive functions which have been described as explaining impaired MDC 
include cognitive communicative functions such as verbal reasoning,31 verbal memory,31,36 
verbal fluency37 and confrontational naming.38 A review regarding future thinking in demen-
tia concluded that deficits in episodic memory, semantic memory and executive functions 
contribute to impairment.39 Overall cognitive deficits  show correlation to impaired MDC, as 
well as large intra-test variability between test-sessions.33 
Whilst there is a justified demand for specificity regarding definition and assessment in MDC 
in order to better understand its neuropsychological attributes, the four-component model 
has been criticized due to its narrow focus on cognition.25,34 Intra-personal factors besides 
cognition that can contribute to MDC include a person’s beliefs, values, emotions40-42 
and measures of insight.43,44 Standardized tests for MDC, however, only assess cognitive 
functions.
1.2.3	 Assessing	medical	decision-making	capacity	in	geriatric	patients
The first factor when considering whether to assess MDC is patients and their conditions. 
Adults are assumed to have unimpaired MDC unless otherwise indicated, but this may be an 
over-simplification for the geriatric population. Among very old individuals in senior hou-
sing facilities, even subtle cognitive decline was shown to affect their MDC.45 Conditions 
where a non-negligible number of affected patients have impaired MDC (temporarily, decli-
ning or permanently) are for example neurodegenerative diseases like AD and Parkinson’s 
disease,44,46-49 certain psychiatric disorders50 and traumatic brain injury.51 A majority of patient 
– caregiver encounters in clinical work or medical research do not involve explicit assess-
ment of MDC.52 A clinician or researcher accepting a patient’s choice has, however, implicit-
ly accepted the patient’s MDC as adequate. When a patient presents with any disease known 
to affect cognition or communication, assessment of MDC should be considered.29
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Semi-structured interviews are a clinical approach to formalize assessment of MDC. The 
interviews include open-ended, specific, questions regarding the decision to be made. The 
questions address at least one, but may include all four components of MDC. A semi- 
structural approach regards a specific decision at hand. The first question should 
probe the patient’s understanding. Any misunderstanding should be corrected before procee-
ding with questions regarding decision and reasoning. Worth noting is that semi-structured 
interviews include a teach-back procedure, thus tending toward facilitation of the patient’s 
understanding rather than pure assessment of his/her MDC. Performing a semi-structured 
interview can increase interrater agreement as compared to relying entirely on clinicians’ 
subjective opinions regarding patients’ MDC.29 
The most comprehensive level for assessing MDC uses standardized tests. The assessments 
commonly include information, a standardized interview and scoring. Validation of tests 
assessing MDC struggles with the fact that even though all tests are based on one, several 
or all four cognitive components, correlations to clinical judgment of patients’ MDC are 
low.53 Test constructors have used the non-congruent results to argue the need for standar-
dized protocols, while others have raised the question of whether the tests really are valid 
to assess MDC.25,54,55 The definition of MDC was originally developed from definitions of 
juridical competence and a theoretical line of argument regarding what capacities it is re-
asonable to assume are a valid part of MDC. The construct validity itself of the concept 
MDC is therefore not self-evident. Consequently, comparing existing tests is not simple. A 
Cochrane review of tests that assess MDC was later withdrawn, due to the lack of a consistent 
definition.56,57 
Existing tests concern decisions relating to either treatment or research, both types assess an 
overall MDC based on a hypothetical situation or a specific decision in real life. In Figure 2, 
existing tests are plotted with regard to whether the test uses the vignette method or a real-life 
decision, and whether it assesses informed consent to medical research or regular treatment 
decisions. All tests included have been developed for and/or validated in a geriatric popula-
tion.25,54 
When assessing a potential participant’s capacity to give informed consent the vignette 
method is typically utilized, where written and verbal information regarding a hypothetical 
clinical trial is presented. Immediately afterward, a standardized interview is carried out to 
assess MDC. The interviews are transcribed and/or scored according to the test’s protocol.58,59 
Tests using the vignette method exist in several languages, with MacArthur competence 
assessment tool for clinical research (MacCAT-CR) as the most widely used test.25,54,60,61
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MacCAT-CR consists of a vignette and a standardized interview assessing the original 
four components of MDC, with an emphasis on understanding (13 questions) followed by 
appreciation (three questions), reasoning (four questions) and expressing a choice (one ques-
tion). The test takes approximately 20 minutes to complete. Sub-scores and a total score are 
obtained, but there is no cut-off score indicating if a patient has impaired MDC. 
Swedish linguistic instrument for medical decision-making (LIMD) assesses capacity to 
give informed consent. The original four components of MDC were merged to three: 1) 
comprehension (understanding), 2) evaluation (combining appreciation and reasoning) 
and 3) intelligibility (expression of a choice). The aim was to exclude a subjective opinion 
whether a patient’s reasoning was logical or not, and instead add focus on linguistic factors 
in the participants responses. Necessary linguistic abilities include receptive language and 
ability to express oneself, but cognitive abilities are also important, e.g., in order to reason 
and compare risks versus benefits. The original study included three vignettes with informa-
tion about hypothetical drug trials with different levels of potential risks and benefits. LIMD 
is an extensive and time-consuming test; each vignette first is read aloud, followed by a 
standardized interview, verbatim transcription and scoring. LIMD’s primary use is when an 
in-depth assessment is warranted in research.24 Given the cumbersome nature of existing tests 
regarding capacity to give informed consent, there was need for a more user-friendly test. 
Clinical instrument of medical decision-making capacity (KIMB) was specifically construc-
ted to be fast and easy to use. KIMB is purely text-based, in contrast to MacCAT-CR and 
LIMD, which contain standardized interviews. The vignette concerns a hypothetical 
Figure 2. An overview of tests measuring medical decision-making capacity.
© Liv Thalén, 2019
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clinical trial. The text has 13 embedded tasks assessing reading comprehension. The vignette 
is followed by a multiple-choice questionnaire which assesses comprehension, evaluation 
and choice. KIMB contributes to and complements previous tests assessing capacity to give 
informed consent with its features: 1) being fast to complete, 2) using the vignette method, 3) 
including a fictitious person in the hypothetical vignette. The test construction is thoroughly 
described in Methodological considerations.
In contrast to the above-mentioned tests that utilize the vignette method, the University of 
California brief assessment of capacity to consent (UBACC) uses a specified protocol that 
needs to be adapted to each specific situation. The questionnaire does not require the patient 
to express an intelligible choice, but includes a teach back process to correct any misunder-
standing.62-64 It could therefore be argued that UBACC accesses the best available decision 
rather than purely assessing capacity to give informed consent. The test can be completed in 
just five minutes. 
Among tests which regard treatment decisions, the MacArthur competence assessment tool 
for treatment (MacCAT-T) is similar to its equivalent MacCAT-CR. A structured interview 
approach is used to assess MDC, typically within 20 minutes. Unlike MacCAT-CR, where a 
hypothetical vignette is used, MacCAT-T incorporates the information and decision at hand 
for the patient.26 Assessment of capacity for everyday decisions (ACED) has a functional 
and specific focus on patients’ decision-making capacity regarding activities of daily living. 
A structured interview with written information is performed, and the score is presented in 
six sub-areas.43 In contrast to MacCAT-T and ACED, which both use information concerning 
a real-life situation for the patient, the Capacity to consent to treatment interview (CCTI) 
utilizes the vignette method with two hypothetical treatment decision as written fundament, 
followed by a standardized interview. The score is expressed in terms of adherence to five 
legal standards. CCTI can be completed within 25 minutes.65
1.2.4	 The	impact	of	cognitive	impairment	and	other	intra-personal	factors
MDC is typically affected negatively already in mild to moderate stages of AD.24,32,65-69 
Problems arise particularly in the contexts of understanding, reasoning and appreciating,37,65,70 
but also in evaluating risks and benefits and expressing a decision.24 Examples of cognitive 
communicative capacities affected in early stages of AD are abstract thinking, reasoning and 
using figurative language. These capacities are needed to comprehend and make informed 
medical decisions, but also to imagine what consequences different decisions have.71,72 The 
cognitive communicative problems that accompany with AD probably affect the possibility 
of successfully carrying out a standardized assessment of MDC. Reduced reading ability may 
contribute to impaired MDC, especially regarding informed consent where the information is 
extensive.73-76 While individuals with AD have impaired MDC early on, exceptions do exist 
where individuals with AD are still able to give informed consent.33
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Pragmatic communication problems, possibly due to impairment in working memory, 
episodic memory and attention problems, also arise during the course of AD. The pragmatic 
difficulties manifest for example in repeated questions and misunderstandings.76-78 The more 
complex the information, the more difficulties a patient with AD will have perceiving it.76 
Inference – the ability to draw conclusions from information received – deteriorates, which 
hinders the patient from reasoning and appreciating information related to the decision that is 
to be made. Anomia in AD results in circumlocutions and the tip of the tongue phenomenon.79 
Together, the various communicative difficulties realized in AD make it hard for the commu-
nication partner to understand what the individual wants to express.78,80
Patients with MCI do not exhibit as impaired MDC as patients with AD. Nevertheless, on 
a group level, impaired MDC has consistently been found.24,81,82 A three-year follow up 
comparing patients with MCI and healthy controls showed at baseline that appreciation, 
reasoning and understanding were significantly lower within the MCI group. After three 
years, the MCI group showed a significant decline in understanding. The decline was most 
prominent for individuals who had had their diagnosis converted to AD.67
Advanced age is a joint risk-factor for multimorbidity and cognitive impairment alike.83 
Patients with AD have been reported to have at least one comorbidity in 94% of the cases.84 
Studies have either taken the approach that dementia increases risk for multimorbidity,85 or 
the other way around.86 The relationship between dementia and multimorbidity is complex.87 
Additive as well as interactive effects have been suggested between co-occurring cognitive 
impairment and multimorbidity,88 resulting in for example accelerated decline in ADL89 and 
worse day to day functioning.90 Cerebrovascular diseases have been reported to especially 
increase risk for impaired cognitive functions.91 Somatically ill in-patients without cognitive 
impairment have also been found to have impaired MDC.52,92,93 
Intra-personal factors which have been observed are a patient’s beliefs and values, 
authenticity, emotions40-42 and measures of insight.43,44 External factors include the person 
who asks for a decision, and the situation in which the decision-making is taking place,94 
including time.45 Since factors outside the patient can more readily be altered, the exter-
nal factors are important when studying different approaches to support patients in the 
decision-making process. 
MDC as a concept presupposes a desire for and from a patient to make an autonomous deci-
sion. However, a decision is always made in a context. Patients may invite others to discuss 
the matter prior making an important decision. As situations change, decisions may change. 
The inverse is also true; a new decision changes the situation and adds new experiences and 
factors, which in turn can affect decisions later on.94 The next section will discuss medical 
decision-making from a complementing perspective – patient participation.
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1.3 PARTICIPATION IN MEDICAL DECISION-MAKING  
PROCESSES FOR GERIATRIC PATIENTS
1.3.1	 Communicative	aspects	of	participation	in	medical	contexts	
Factors influencing geriatric patients’ opportunities to actively participate in medical deci-
sions can be viewed from three perspectives: patient-related factors, factors associated with 
the health care setting/situation, and factors related to health care provider.94
There is no standardized, coherent method for examining patient participation. As with MDC, 
the diverse measures make it difficult to draw conclusions and compare results between 
studies.95,96 Well-functioning communication is, however, a recurring aspect. A review 
divided factors that affect patient participation into three different categories: the relation and 
communication between patient and caregiver, environmental factors (e.g. time) and last but 
not least, the need to acknowledge the patients’ awareness of his/her situation together with 
his/her values.97 
Well-functioning communication, including that information is presented in an under- 
standable way, is often emphasized as a major factor and prerequisite for any patient partici-
pation.2,97,98 The desire to be well-informed is highlighted as being important to many geriatric 
patients.99-101 Getting information in an understandable way, and having good communication 
with care providers,100 including a trustful relationship, are other important factors.99,102,103 
Communicative skills in healthcare staff have been emphasized as an important factor to 
involve patients in medical decision-making processes.2,98,100 Conversely, communication 
barriers, such as stressed caregivers and lack of shared language with the patient on the other 
hand hinder participation.2,99,104
The term health literacy originates from epidemiologic rather than cognitive 
research. Health literacy involves cognitive functions like ability to read, understand texts and 
numbers in a medical context and evaluating this information with regard to one’s own 
situation. However, intra-personal factors besides cognition are also involved. Know- 
ledge and motivation also affect decisions in medical contexts, including disease prevention, 
self-care management, health promoting behaviors and access to health care platforms.105-108 
Health literacy has been described to exist at different levels, where functional literacy is 
the fundamental skill of reading and writing, followed by the higher level of communicative 
literacy where the abilities can be used to apply information to different situations, and finally 
critical literacy, where information can be scrutinized critically.109
In a survey from Europe, almost half of 8000 citizens from eight different countries showed 
an “insufficient” or “limited” level of health literacy. Poor health literacy was associated to 
several socio-demographic factors such as low income, low social status, low education and 
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old age.110 Lower compliance to medical treatments, worse treatment outcomes and poor 
adherence to self-care are other outcomes associated with low health literacy.107,108 
The extent to which a geriatric patient desires to have an autonomous, active role in health 
care decisions is individual.99,100,102,111-114 Geriatric patients may prefer to make a decision 
together with either formal or informal caregivers, or wish that the decision is made by 
caregivers who have the medical competency. However, other studies have highlighted that 
even among the oldest old patients, some desire to participate, but that actions to facilitate 
communication may be needed to enable their participation.115 A thesis concluded that 
a majority of geriatric patients desire an active role in medical decision-making. Factors 
that hindered participation were found in organizational structures that affected the formal 
caregivers’ opportunities to make a holistic assessment of patients, and the amount of time 
available at the hospital.103 
The organizational context of health care can also affect staff, which in turn may affect 
patient’s participation negatively, for example if the formal caregiver experiences stress due 
to limited resources or time. Environmental factors such as busy surroundings or interrup-
tions can also have an adverse effect on participation. Meeting a large number of formal 
caregivers has been reported to influence participation negatively.2,104,116 
Geriatric patients’ participation has positive side-effects. Patients express greater satisfaction 
with care provided,97 increased trust in health care staff, and more positive and direct com-
munication. Enhanced adherence to treatment and personal motivation to improve health, 
together with better health and quality of life have also been reported.2,97
1.3.2	 Participation	in	discharge	planning	meetings
Until recently, discharge planning meetings were standard at Swedish geriatric wards prior 
discharge of a patient. The aim was to ensure continued care at an appropriate level, whether 
at home or at another care facility. In autumn 2018, the legislation was changed and discharge 
meetings were replaced by Coordinated Individual Plans (in Swedish: Samordnad individuell 
vårdplan), which are typically created outside the hospital, after discharge. Since this change 
took place at the very end of this doctoral project, the focus within the thesis summary is still 
discharge meetings.
Two major factors are highlighted in the literature regarding geriatric patients’ participation 
in discharge meetings: patients’ preferences and communication. The patient needs to feel 
included and listened to, but the importance of attitudes, knowledge and skills of staff, as well 
as the environmental setting, were highlighted in a review.2 Figure 3 illustrates facilitators 
of well-functioning communication and participation in discharge meetings, arranged accor-
ding to whether they are applied before or during the meeting. 
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Factors listed under Before the meeting in Figure 3 aim to increase patient participation 
during the meeting. Several studies have highlighted the importance of preparing the 
patient prior the discharge meeting. It may seem obvious that the patient should be prepared 
before the meeting, but this is not always done.117-120 The patient needs to know the aim and 
general outline of the discharge meeting.98,121,122 Communication is needed within the hospi-
tal, between patient and caregiver and within the team caring for the patient, but also with 
external stakeholders like representatives from the municipality and, if applicable, the patient’s 
family.98 Quality of communication during discharge meetings has been highlighted as 
crucial for patient participation in several studies.123-125
1.4 COGNITIVE COMMUNICATIVE APPROACHES TO SUPPORT 
GERIATRIC PATIENTS IN MEDICAL DECISION-MAKING 
PROCESSES
The structured methods to facilitate geriatric patients’ participation in medical decision- 
making processes can be divided into three categories depending on who or how the method 
is intended to support or facilitate: 1) support the patient, 2) facilitate the situation and 3) 
enhance caregiver’s communicative skills. Facilitating the caregiver’s skills will not be 
addressed here, since it is not a method used within this thesis. Figure 4 shows a three-way 
perspective on factors influencing geriatric patients’ participation in medical decision- 
making processes.  
Figure 3. Identified key factors in communication which can act as facilitators of patient participation in 
discharge planning meetings. 
© Liv Thalén, 2019
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1.4.1	 Support	the	patient
Communicative memory aids are considered to support both cognitive and communicative 
skills, by helping the patient find words, recall memories and stay on topic. The aids can 
consist of drawings, photographs, individual words and/or phrases. The aids aim to take 
advantage of the often preserved automatic speech, as well as the desire to communicate.126 
One example of a method using a cognitive communicative based approached with pictures 
and/or words is Talking mats (TM). 
TM is a method which facilitates for an individual to organize thoughts and express opinions. 
Its foundation is a textured mat showing a scale illustrated with simple images that express 
a person’s opinion (ranging for example from “I like it” to “I do not like it”). The mat is 
placed before the person in need of support, and questions are posed, one at a time, each one 
illustrated with one picture, and often a keyword below the picture. The respondent gives his 
or her answer by placing the picture below the scale step they think is appropriate, along with 
any verbal response if possible. This visualizes the respondent’s answers and put the answers 
in relation to each other, helping to compare them. While the method aims to support the 
patient, the caregiver is the one who needs to learn the method, and also prepare each topic 
and pictures.127 
Previous studies have shown that when individuals with dementia use TM it increases com-
munication efficiency by enhancing their understanding, their engagement in conversation 
and their ability to keep on track. Crucially, they were understood to a greater extent than 
Figure 4. Factors influencing a geriatric patient’s possibilities to participate in medical decision-making 
processes. Words in black indicate areas investigated within the doctoral project. Other aspects, covered 
in the background, are included to give a wider perspective. The responsibility of staff to examine and 
promote best available participation is high-lighted in Discussion.
© Liv Thalén, 2019
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when they participated in a structured or non-structured interview.127 Both patients and their 
informal caregivers reported positive outcomes in terms of clarifying thoughts and feeling 
more listened to. In contrast to many other suggested models and methods,126,128 TM has been 
evaluated using measures of communication outcomes.127
1.4.2	 Change	factors	in	the	situation
One way to facilitate understanding is to increase readability of participant information, using 
simpler language and/or complementary written information with pictures.30,129 Linguistic 
elements that make a text more or less difficult to understand are well known. Among them 
are mean sentence length, mean word length, number of difficult words, how many subor-
dinate clauses there are on average per sentence, mean parse tree height and idea density.130 
The readability of written information to patients can be improved by choosing the linguistic 
structure carefully. However, when it comes to informed consent to hypothetical trials, the 
readability may not be the most important obstacle to overcome.131
Information to participants in medical research contains medical and technical terms that 
are rarely used in everyday speech, but which cannot be excluded without loss of vital 
information. The level of difficulty in participant information often surpasses the level 
that readers are assumed to understand.132 A study comparing patients’ understanding of a 
standard information consent document versus an improved consent document (improved 
by altering structure and readability) found no objective improvement in understanding.131 
Trying to increase readability does not necessarily improve participants’ ability to give truly 
informed consents.131,133-136
1.5 COMPARING MEDICAL DECISION-MAKING CAPACITY,  
PATIENT PARTICIPATION AND HEALTH LITERACY –  
A SUMMARY
Communication is a necessary topic when discussing geriatric patients’ medical decision- 
making capacity, participation and health literacy alike. Sufficient hearing, vision and a 
shared language are basic requirements. Receptive linguistic skills are fundamental to 
participation in medical decision-making process. Understanding is the first requirement 
before it is possible to process and act on information. Understanding is highlighted in MDC, 
patient participation and health literacy alike. Cognitive communication functions are needed 
to process information and reach a decision. MDC, patient participation and health literacy 
emphasize the need to ponder information and apply it to one’s own situation. Expressive 
language skills are important in MDC, patient participation and health literacy alike, in order 
to communicate a choice. However, while MDC focuses on the ability to provide a clear and 
consistent choice, patient participation and health literacy also concern the patient’s ability 
to provide information to the caregiver, regarding for example symptoms or preferences. 
A compilation of three communicative aspects of decision-making in medical contexts 
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is found in Figure 5. The overall aim of this thesis is to investigate medical decision- 
making capacity in geriatric patients with and without dementia using communication-based 
approaches to assessment and facilitation.
Figure 5. Three aspects of communication in medical decision-making processes – found in the upper 
boxes – derived from definitions of medical decision-making capacity, health literacy and patient partici-
pation. The boxes in the middle row are included in all three definitions, while the boxes in the bottom row 
contain aspects only included in definitions of health literacy and patient participation. The boxes in black 
are addressed within the studies included in this thesis, while boxes in grey are not.
                                                                                                                          © Liv Thalén, 2019        
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2 METHODOLOGICAL CONSIDERATIONS
2.1 PARTICIPANTS
The projects included geriatric patients with and without dementia, in-patients and out- 
patients, as well as a healthy control group. Table 1 contains an overview of the participants 
in each study, including number of subjects, inclusion criteria, participants’ mean age, mean 
score on cognitive screening tests and mean years of formal education. 
Study I concerned geriatric in-patients with cognitive impairment, while study IV included 
geriatric in-patients without known cognitive impairment. The two studies that included 
out-patients also had participants both with and without dementia. Only participants with 
Alzheimer’s disease (AD) were recruited for study II, while participants with AD, Mild 
cognitive impairment (MCI) and healthy controls were included in study III. 
Clinical investigation of patients with suspected AD at the memory clinic followed criteria 
in ICD-10 and internationally established diagnostic standards.137 AD is characterized by 
an insidious onset and progressing impairment of cognitive functions. Deficits in memory 
typically appear first and are most readily noted. Other effects that appear early are language 
impairment, worsened perception, and difficulties with abstract thinking.7,8 For the studies 
reported here, a multi-disciplinary team performed a clinical examination, routine laboratory 
status, status regarding daily life and cognitive functions and a magnetic resonance ima-
ging of brain. Cerebrospinal fluid biomarkers were analyzed unless contraindications were 
present. In the recruitment procedure for study II and III, participants with cognitive impair-
ment were required to score at least 20 points on Mini-mental state examination (MMSE), 
a screening test of overall cognitive function.138 It was postulated that patients who scored 
lower would not be able to participate in the test situation. Diagnosis criteria for MCI 
include subjective complaints of declines in cognitive functions which could be verified with 
objective tests. Other inclusion criteria were adequate global cognitive function and preser-
ved activities of daily life.9
A difference between the studies’ focuses was whether the primary aim was to investigate a 
specific method, or to describe a specific aspect of reality at hospital wards at a given time. 
Study I and IV aimed to reflect actual status at wards, and therefore had more generous 
inclusion criteria than study II and III. For study II and III, Swedish was required as the 
participant’s native language, or one of them if bilingual. For study I and IV the inclusion 
criterion was instead set to ability to communicate in Swedish without an interpreter. A 
similar distinction between the studies regarded depression. Depression as measured by a 
score on Cornell’s depression scale ≥ 9138B was an exclusion criterion in study II and III, but 
not in study I and IV. Study I and IV overall had similar inclusion/exclusion criteria, with the 
exception of documented cognitive impairment. A patient with severe aphasia was excluded 
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mainly because it was impossible to gain informed consent, but the patient would have been 
unable to participate in the test situation. The use of different samples in the different studies 
warrants caution when integrating and interpreting the results. 
The inclusion procedure varied between studies. For study I and IV, in-patients were 
asked to participate in the respective studies, whereas for study II and III, a letter of invitation was 
sent to patients’ homes. Compilations from weekly diagnostic rounds at a university hospital’s 
memory clinic were used to identify possible participants. Healthy controls for study III were 
recruited as part of a master’s thesis.139 All participants were recruited within the wider 
geographic region of Stockholm. 
The mean age of groups diagnosed with AD was 73.6±8.2 in study II, and even lower, 
67.3±7.2, in study III. This participant age span, relatively low among publications dealing 
with AD, might reflect today’s clinical interest in diagnosing AD as early as possible. The 
in-patients with dementia or other cognitive impairment included in study I had similar mean 
ages in Talking mats group (TMG) and Control group (CG). The highest mean age was found 
in the group of in-patients without known cognitive impairment who participated in study IV: 
82.0±7.3 years. 
A comparison of the participants’ actual screened overall cognitive function showed that par-
ticipants in study IV, for which known cognitive impairment or acute confusion was an expli-
cit exclusion criterion, had mean scores as low as those of the participants with documented 
cognitive impairment in the other studies. As a group, these in-patients with somatic illnesses 
showed a screened overall cognition at dementia level. 
Nota bene that two different tests were used to screen overall cognitive function: MMSE138 
and Montreal cognitive assessment (MOCA).140 MMSE has an original passing cut-off score 
of 24/30, but it has been argued that, especially for individuals with longer formal education, 
this may be too low to detect subtle cognitive impairment.141,142 MOCA on the other hand 
has a higher original passing cut-off score, 26/30. Even though a correction for short formal 
education is made when scoring, a meta-analysis argued that the cut-off score should be even 
lower.143 MOCA was preferred to MMSE in study III and IV due to its ability to detect subtle 
changes in cognitive impairment.144,145 
 
30 31
Table 1. An overview of participant data.
Study I Study II Study III Study IV
Number of  
participants
TMG, n = 12
CG, n = 8
n = 24 AD, n = 28
MCI, n = 14
HCG, n = 21
n = 44
Inclusion criteria
Language Communicate in 
Swedish without 
interpreter
Swedish as (one of) native  
language(s)
Communicate in 
Swedish without 
interpreter
Hearing and vision No severe hearing or vision impairment that was not corrected by aids
Depression
Not a criterion
No depression
Not a criterionDyslexia No self-reported dyslexia
Cognitive status Documented  
cognitive  
impairment
Diagnosed with AD 
within last  
12 months  
(MMSE ≥ 20 p)
Diagnosed with AD 
or MCI within last 
12 months 
(MMSE ≥ 20 p)
No documented 
cognitive  
impairment
Additional criteria Ability to use  
Talking mats
No additional 
criteria
HCG: No  
diagnosis that 
affects language/ 
cognitive ability 
(self-reported)
No severe 
general condition 
No acute  
confusion
Age in years TMG: 
M = 76.8, 
CG: M = 70.8
M = 73.6 AD: M = 67.3
MCI: M = 65.9
HCG: M = 63.8
M = 82.0
Screening of 
overall cognitive 
function (score)
MMSE
TMG:
M = 21.4
CG: M = 20.3
MOCA
M = 24.7
MOCA
AD: M = 19.5 
MCI: M = 24.3
HCG: M = 27.0
MOCA
M = 21.2
Formal  
education (years)
Not documented M = 10.3 AD: M = 10.9 
MCI: M = 12.5
HCG: M = 12.2
M = 10.2
AD  =  Alzheimer’s disease
CG  =  Control group (patients) 
HCG  =  Healthy control group 
MCI  =  Mild cognitive impairment 
MMSE  =  Mini-mental state examination156 
MOCA  =  Montreal cognitive assessment157
TMG  =  Talking mats group
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Table 2. Overview of study design
Study I Study II Study III Study IV
Aim Facilitation: 
Evaluating Talking 
mats in discharge 
planning meetings
Facilitation:  
Evaluating Adapted 
vignettes for  
patients with  
Alzheimer’s  
disease
Assessment:  
Developing and 
validating KIMB, a 
test to detect  
impaired MDC
Assessment:  
Investigating  
prevalence of  
impaired MDC  
measured with 
KIMB among 
in-patients
Design Prospective,  
randomized  
controlled trial
Prospective,  
randomized  
controlled trial 
Prospective,  
cross-sectional 
design 
Prospective, 
cross-sectional 
design
Settings Geriatric ward Out-patients Out-patients,  
healthy controls
Geriatric wards
Data collection 
period
June 2013 –  
June 2014
Aug 2014 –  
Sept 2015 
Sept 2015 –  
Sept 2017
Jan – March 2018
Data  
analysis 
Evaluation by VAS 
(patient, family, 
nurse, social care 
worker)
Evaluation by 
LIMD
Evaluation of 
validity 
Evaluation by 
KIMB and  
investigating risk 
factors
Ethical  
approval  
reference  
number 
2013/167-31/1 2008/1764-32 2008/1276-31/2 
and  
2009/1764-32
2017/1917-31/1
KIMB = Clinical instrument of medical decision-making capacity 
LIMD = Swedish linguistic instrument for medical decision-making
MDC = Medical decision-making capacity
VAS = Visual analogue scale (100 mm)
32 33
2.2 SETTING AND DESIGN
In order to obtain a representative sample from the population, the studies in this thesis 
shared a prospective, consecutive study design, with predefined study protocols including 
inclusion and exclusion criteria. Table 2 gives an overview of the studies’ designs, including 
aims, settings, data collection periods, data analysis and ethical approval reference numbers 
from the regional ethics committee in Stockholm. In study I, the setting was a geriatric ward 
where patients with suspected dementia were examined and diagnosed by a multi-professi-
onal team, whereas in study IV the setting was three geriatric wards with focus on stroke/
neurological diseases and multi-morbidity/internal medicine.
A holistic approach was sought by including both studies that focused on facilitation and on 
assessment in medical decision-making processes. Within this framework, it was possible to 
integrate and interpret results from different settings, that involved different materials and 
participants. Study I and II evaluated one intervention procedure each: Talking mats and 
Adapted vignettes. In study III, the focus was on the construction and validation of a text- 
based test to detect impaired medical decision-making capacity (MDC). Study IV investigated 
prevalence of impaired medical decision-making capacity among geriatric in-patients without 
known cognitive impairment. 
One endeavor in all studies was that meetings with participants should take place in an as 
calm an environment as possible. For participants recruited outside the hospital, this was a 
minor problem. A quiet room was readily available regardless of whether the participant was 
met at the clinic or in his/her own home. On the other hand, in-patients commonly shared a 
room with at least one other patient. While the wards had small rooms used, for example, for 
discharge meetings and team rounds, some background noise was typically noted.
In study II each participant read the vignettes in a different and unique order, so as to 
eliminate any test order effect. Conversely, test order was the same for all participants in 
study III and IV to ensure that any test order bias would be constant.
2.3 MATERIAL
2.3.1	 Talking	mats
Talking mats (TM) was used to help patients prepare prior to discharge meetings in study I. 
The subject addressed in the TM session was labeled “you”, to focus on the patient’s own 
ability to perform activities of daily living and need of assistance and care after discharge. 
Questions appropriate to include in the TM session were those likely to be discussed during 
the discharge meeting. The questions were identified by participating in discharge meetings 
at the ward. Suggested questions were discussed with an experienced nurse at the ward. In 
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total, 26 pictures were prepared, but each participant chose which pictures/questions felt 
relevant to him/her. In study I, Figure 1 shows examples of pictures used. 
Communication in each discharge meeting was evaluated afterwards by patients, a 
family member, nurses and social care workers on visual analogue scales (VAS). All persons 
attending the discharge meetings were informed about the study prior to the meeting, and the 
evaluation sheets were presented. Sheets for each group (patients, family members, nurses, 
social care workers) were left in the room, together with an instruction that if anyone wanted 
to participate, they could fill in the VAS immediately after the meeting.  
The statements on VAS aimed to address the patient’s communication, and therefore differed 
in pronoun, for example: I have understood what we have been talking about as compared 
to I perceive that the patient understood what we have been talking about. Each statement 
on the patient’s paper with VAS was illustrated using the same scale picture as in the TM 
session. Figure 6 shows an example of a statement used for evaluation. In this study, there 
was no objective analysis of actual communication; rather, the focus was the participants’ 
experiences of the communication. 
Figure 6. First statement on the visual analogue scale to evaluate how communication had been functi-
oning during the discharge planning meeting in study I, with an English translation below.
Source: Personal collection
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2.3.2	 Swedish	linguistic	instrument	for	medical	decision-making
The original version of the test Swedish linguistic instrument for medical decision- 
making (LIMD) included three vignettes: Kidney disease, Hypertension and Skin disease. The 
hypothetical clinical trials presented in the vignettes regarded evaluation of new medical 
treatments. The trials differed with regard to potential risks and benefits for participating 
subjects. The texts with information to possible participants also differed in terms 
of how serious the imagined underlying disease was. The Kidney disease vignette 
described a hypothetical trial with low personal risk and high potential benefit in 249 words. 
The Hypertension vignette described a trial with high personal risk and low potential 
benefit in 525 words. In the Skin disease vignette, an intermediate personal risk was accom-
panied by an intermediate potential benefit. 
When using LIMD to assess an individual’s understanding, the assessor read aloud to 
the participant, one vignette at a time, but the participant could read along in his/her own 
copy of the vignette. After each vignette, a standardized interview with nine questions 
followed. The standardized interview assessed MDC according to three aspects 
defined in LIMD: comprehension, evaluation and intelligibility of choice. The 
interviews were audio recorded, transcribed and scored according to LIMD’s 
protocol based on linguistic features.24 Figure 7 shows excerpts from the questions 
used in the standardized interview. The validation study of LIMD included partici-
pants with early stage AD, MCI and healthy controls. Intra-rater reliability was high 
(r = .94), as was the inter-rater reliability (r = .89).24 For study II, a new intra-rater reliabi- 
lity was calculated by re-scoring 20 interviews (r = .89). The 20 interviews were selected to 
represent a range of scores, from minimum to maximum. 
2.3.3	 Adapted	vignettes
A comprehensive linguistic analysis based on responses made by persons with AD in the 
LIMD validation-study was performed. The aim was to identify which linguistic features 
were difficult for patients with AD to comprehend, and after identifying these features, 
make the information easier to understand by altering these constructions. The six identified 
difficult features were: 1) long sentences, 2) subordinate clauses, 3) compound word and 
technical terms, 4) words with negative association, 5) passive verbs and 6) comparatives. 
The project resulted in two new, linguistically adapted vignettes, which were hypothesized to 
facilitate understanding for patients with AD.146 The material used in study II was two of the 
original vignettes in LIMD (Kidney disease and Hypertension), and their two corresponding 
Adapted vignettes. Figure 8 shows a flow chart of the process to create the Adapted vignettes.
In study II, each participant read the original Hypertension and Kidney disease vignettes, 
as well as their two corresponding Adapted vignettes, to compare if Adapted vignettes 
facilitated MDC. The interviews were audio recorded and afterwards anonymized and trans-
cribed verbatim prior to scoring.
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Source: Adapted from Daniela Gabrielsson, 2013,146 with permission.
Figure 8. The process of linguistically adapting the original Hypertension and Kidney disease 
vignettes in order to create Adapted vignettes, which were hypothesized to be easier for persons with 
AD to comprehend.
© Adapted from the LIMD protocol, Liv Thalén, 2019
Figure 7. Excerpts from the questions included in the standardized interview concerning Swedish 
linguistic instrument for medical decision-making (LIMD), grouped by which aspect of medical 
decision-making capacity they aimed to assess: comprehension, evaluation or intelligibility of choice. 
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2.3.4	 Sentence	 structure,	 vocabulary	 load,	 idea	 density,	 and	 human	 and	 
personal	interest
Sentence structure, vocabulary load, idea density, and human and personal interest (SVIT) 
is a computer-based method to assess the readability of a text using surface features and 
deep linguistic features.130 The SVIT method was used to compare original and adapted vig-
nettes, and to describe linguistic features of KIMB. A text’s surface features lie in its actual 
form, such as number of words per sentence. The deeper linguistic features include voca- 
bulary, sentence structure and idea density. Vocabulary load is calculated by counting words 
not included in SweVoc, which is a Swedish vocabulary list consisting of the 7100 most 
commonly used lemma words.149 The syntactic complexity in sentence structure is analyzed 
using parse tree derivation. Each sentence is organized and labelled based on its syntac-
tic structure, which is distinguished from the sentence’s meaning. This organization results 
in hierarchical nodes. Counting these nodes gives a measure of syntactical complexity; the 
higher the number of nodes, the more syntactically complex is the sentence. Figure 9 shows 
an example of a parse tree. Idea density is calculated as the number of nouns, prepositions 
and participles divided by the number of verbs, pronouns and adverbs.130 
2.3.5	 Clinical	instrument	of	medical	decision-making	capacity
The Clinical instrument of medical decision-making capacity (KIMB) was constructed with 
the aim to be fast and easy to use in medical contexts and can typically be completed within 
ten minutes. KIMB was based on the vignette method and a hypothetical clinical trial, thus 
measuring the capacity to give informed consent, based on a hypothetical situation.
The following guiding principles were applied in the construction of KIMB:
• The vignette should concern MDC for informed consent.
• The content should cover comprehension, evaluation and decision. 
• Deep and surface language characteristics of the test should be similar to those of 
the test Diagnostic material for analysis of reading and writing skills (DLS) Reading 
speed, which assesses reading speed and reading comprehension. The test should also 
have similar construction with embedded brackets containing three word to chose from 
as DLS Reading speed.147 The reason was twofold: 1) DLS Reading speed showed 
strongest correlation to MDC as measured with LIMD in a previous study,32 and 2) 
previous studies had shown that patients with early stage of AD could read the text.32,133 
Surface and deep language structure were analyzed using SVIT.130 A compilation of the 
SVIT analysis is presented in study III, Table 1. 
• Tasks should engage all five reading levels as described by Mullis et al.148:
1. Recognize words and phrases
2. Understand sentences and simple paragraphs
3. Retrieve explicitly stated information
4. Make straightforward inferences
5. Comprehend the overall message
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KIMB emphasizes the role of reading skills in MDC, since KIMB contains two written 
tasks, but no interview. The participant’s task was first to identify target words within the 
vignette, then complete a questionnaire. Throughout the vignette were embedded comprehen-
sion tasks where the right word out of three in a bracket should be chosen while reading the text. 
The questionnaire consisted of multiple-choice questions based on the information from the 
vignette. The questions addressed comprehension, evaluation and choice.
While KIMB shared LIMD’s focus on linguistic features in MDC, the test had innova- 
tive features. The vignette was written in third person instead of first person pronoun. By 
naming a fictitious character, the test constructors sought to minimize the risk of confusing 
persons with dementia. Furthermore, the idea of using a vignette to assess understanding 
while reading, and subsequently using the same vignette to assess all three aspects of MDC 
was a new approach. Figure 10 shows a compilation of tasks in KIMB, and Figure 11 three 
examples of tasks from KIMB. 
© Adapted from the KIMB protocol, Liv Thalén, 2019
Figure 10. A compilation of tasks in Clinical instrument of medical decision-making 
capacity (KIMB), grouped by which aspect they aimed to assess: comprehension, 
evaluation and choice. 
S    = sentence (root node)
N = noun (leaf node)
NP = noun phrase (branch node)
V  = verb (leaf node)
VP  = verb phrase (branch node)
D  = determiner (leaf node)
                                                                                           © Liv Thalén, 2019
Figure 9. An example of a parse tree with five node levels.
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1.  Dolorsjukan kan [smitta forcera drabba] både män och kvinnor och debuterar  
vanligtvis runt 50-60 års ålder.
2. Vad handlar texten om?
 o Erbjudande om en gratis och välbeprövad medicin
 o Undersökning av effekten hos ett nytt läkemedel
 o Behandling för att minska kramper
3. Hur stor nytta har Kim av att delta i studien?
 
 o   o  o  o
 Mycket liten Liten  Stor  Mycket stor
1.  The Dolor disease can [infect crash strike] men and women alike and usually has an 
onset around the age of 50-60 years.
2. What is the text about?
 o Offer of a free and proven medication
 o Investigating the effect of a new drug
 o Treatment to reduce seizures
3. How much benefit does Kim have by participating in the study?
 
 o   o  o  o
 Very small  Small  Large  Very large
Source: Adapted from Clinical instrument of medical decision-making capacity, personal collection
Figure 11. Examples from Clinical instrument of medical decision-making capacity, showing three types of 
tasks set for participants: 1) selecting the right word, 2) demonstrating understanding, and 3) evaluating the 
information. The examples in Swedish are followed by English translations. 
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The following steps were applied before the final version of KIMB was decided on and the 
validity study was carried out:
1. A first version was constructed.
2. Colleagues voluntarily tried KIMB and gave feedback. 
3. A group of voluntary speech and language pathology students tried KIMB.
4. KIMB was adjusted, mainly with respect to phrasing in the questionnaire, in order to 
avoid ambigouness.
5. Each task in the first part with embedded words was checked for most common word 
order frequency in a corpus analysis.A  Of the three word choices, the correct word 
was always the one the corpus showed most commonly followed the word before the 
brackets. In some cases, none of the words in brackets were found to follow the word 
before the brackets. The incorrect words were never allowed to be more common after 
the word before the brackets than the correct word – thus avoiding tricky questions. 
6. Groups of healthy controls and of patients were assessed with KIMB and their 
results compared. Healthy controls were recruited among staff at hospital and extended 
networks of older relatives. The patients were seeking care at a speech and language 
pathology clinic.
                                                                                                                         
                                            
A The corpus analysis was performed with “Korp” www.spraakbanken.gu.se, with only medical texts chosen as 
reference.
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In the validation study of KIMB, five other tests were chosen as reference points: DLS 
Reading speed,147 Inference and Repetition of long sentences from the test battery test battery 
of high-level language functions (BeSS),151 Rey auditory verbal learning test (RAVLT),152 
Montreal cognitive assessment battery (MOCA)140 and Word sequence production.154 The 
tests were chosen since they had previously shown strong correlations to MDC as measu-
red by LIMD. The correlations were deemed strong enough to warrant not using LIMD. To 
exclude LIMD was desirable from an ethical point of view: LIMD assessments would have 
been more laborious and time-consuming for the participants. Not using LIMD held advan-
tages for participants that were considered to outweigh the disadvantages of not being able to 
correlate KIMB directly to another test of MDC.
The test orders in study III and IV were determined by the same principles: 
• KIMB was presented first, in order to avoid any effects of other tests.
• The easiest task was presented last.
• DLS Reading speed should not follow immediately after KIMB.
Apart from LIMD, no tests required a specific analysis but answers were simply marked right 
or wrong, or in the case of timed tasks such as Word sequence forward, time to completion. 
No inter- or intra-rater reliability tests were therefore performed. Detailed specifications and 
descriptions of the tests included is found in study II-IV. 
2.4 ETHICAL CONSIDERATIONS 
Persons with dementia or other documented cognitive impairment are a vulnerable 
population to include as participants in clinical research. Their cognitive impairment and 
high likelihood of struggling with understanding information and giving truly informed 
consent warrant extra precautions. The two main reasons for including participants with 
different degrees of cognitive impairment in projects in this thesis were: the research questions 
could not be answered by using other participants, and the research results would benefit the 
patient group itself. One important risk to address is that patients may feel dependent on 
health care staff while being at a ward. The person who recruited and tested participants in 
study I and IV was not involved in any of the patients’ ordinary care at the ward. This strategy 
was an attempt to minimize the risk of patients feeling in any way pressured to participate 
in the study. During sessions, it was repeatedly emphasized that participation was voluntary 
and that the patient could withdraw from the study without needing to give any explanation. 
The information given to participants prior to inclusion in any of studies I-III was presented 
both in written form and verbally. All participants had the possibility to ask for clarifications 
and to pose any questions to the researcher. In order to facilitate understanding, an extra sheet 
was added to the standard written participant information with pictures and keywords addres-
sing vital parts of the information for inclusion to study IV.
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2.5 DATA ANALYSIS
All statistical analyses were quantitative and preceded by checking assumptions for each 
respective test. Study I and II mainly used parametric tests, while in study III and IV mainly 
non-parametrical tests were utilized. All calculations were made in SPSS (version 22.0.0.1 
or 24.0.0.0).
In study I, differences between the four groups (patient, next of kin, nurse, social care 
worker) and the three statements were analyzed using a two-way independent ANOVA, 
since beside differences between groups, also any interaction effect was deemed of value to 
investigate. The dependent variable (score on VAS) was continuous, while the two independent 
variables (group and statement) were categorical. All observations were mutually inde- 
pendent. There were no significant outliers as evaluated by z-scores (±2.0), and the data 
were approximately normally distributed for each combination of the two independent 
variables. Not all combinations of the independent variables showed a homogeneity of 
variances (as checked with Levene’s test for homogeneity), but the violations were deemed 
non-significant. 
Differences in the total score on VAS (Statement 1 + 2 + 3) between discharge meetings that 
used Talking mats and those that did not were investigated with an independent samples t-test. 
The dependent variable was continuous, the independent variables were the two categorical 
groups. There was an independence of observation, and no significant outliers as evaluated 
by z-scores. The dependent variable was approximately normally distributed for both groups, 
checked with Shapiro-Wilk test (r>0.0). Homogeneity of variance was not calculated since 
groups were approximately equally large. The effect size was calculated using Hedge’s g, a 
measure based on standard deviations. Hedge’s g can preferably be used for small samples 
since Cohen’s d overestimates the variance explained in the population.
In study II, any differences on LIMD score in relation to the two within factors – 
readability (Original or Adapted vignettes) and type of hypothetical trial (Hypertensi-
on or Kidney disease) – were analyzed using a two-way repeated measures ANOVA. 
Beside differences between groups, any interaction effect was also of interest to investi- 
gate. The dependent variable (score on LIMD) was continuous, while the two indepen-
dent variables (readability and trial) were categorical. The observations were related. There 
were no significant outliers as evaluated by z-scores, and approximately normally distri- 
buted data for each combination of the two independent variables. Since both within factors 
only had two levels, the assumption of sphericity was met. The effect size was calculated 
with eta-squared, which is commonly used in ANOVA. The interpretation of eta-squared 
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is straightforward; it is a measure of the proportion in one variable that can be attributed 
to another. However, although eta-squared gives a correct measure of proportion within 
the sample, it overestimates the variance explained in the population, especially in small 
samples, where the use of omega-squared could be considered instead.
Pearson product-moment correlation was used to calculate correlations between scores on 
LIMD and on each of the other included tests. The assumptions of continuous variables, 
linear relationships, no significant outliers and approximately normally distributed variables 
were met. 
In study III, several of the variables presented either with outliers and/or were not 
normally distributed within each group, and the non-parametric Kruskal-Wallis H test was 
used to investigate any significant differences between the three groups of participants 
(AD, MCI, HCG). The assumptions of Kruskal- Wallis H test were met: the dependent vari-
able was continuous (score on KIMB), the independent variable consisted of three categorical 
groups, there was independence of observations and the distribution of scores for each group 
had approximately the same shape. Mann-Whitney U test was used for pairwise comparisons 
(its assumptions equaling those for Kruskal-Wallis H test besides only two categorical groups 
being allowed). Statistically significant results were defined as r<.05 for Kruskal-Wallis H 
test, and with Bonferroni correction for the multiple post-hoc comparisons, r<.16. Partial 
eta-squared was calculated as measure of effect size. Whereas eta-squared is the proportion 
of total variance explained by another variable, partial eta-squared is the proportion of vari-
ance that is not explained by other variables. This more conservative measure was preferred 
due to use of non-parametric calculations.
The non-parametric test Kendall’s tau–b was used to calculate correlations between scores on 
KIMB and on each of the other tests. The two assumptions of variables being continuous and 
having a monotonic relationship were fulfilled. Kendall’s tau–b was preferred to Spearman’s 
rank correlation coefficient due to the relatively small sample size and relatively high number 
of tied ranks. 
A measure of the overall diagnostic accuracy of KIMB was calculated using ROC curve and 
Area under the curve. Cross-tabulations based on values from ROC curve table were used to 
determine cut-off value for KIMB, and for calculating sensitivity and specificity.
In study IV, a one sample t-test was used to investigate if the sample’s score differed from 
the KIMB cut-off value. The assumptions of continuous variable, independence of observa-
tions, no significant outliers and approximately normally distributed data were met.
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Data for correlations fulfilled criteria for Pearson’s product moment correlation, with 
continuous data, a linear relationship, no significant outliers, and approximately normally 
distributed data as controlled for with Shapiro-Wilk test of normality. 
This study had an explorative approach to risk factors, and did not investigate causational 
relations. Each risk factor was evaluated separately, and no adjustment was made for multiple 
comparisons. Even though the factors were chosen based on previous research, this analysis 
approach increased the possibility of false positive findings (type I errors). Therefore a more 
stringent significance value was set for the correlation analyses: r≤.01. 
The non-parametric Mann Whitney U test was used to investigate any differences on KIMB 
score between those subjects who had Swedish as a first language, and those (only five) who 
had learned Swedish as adults, due to large disparity in group sizes. 
44 45
3 INTEGRATED RESULTS
3.1 MEDICAL DECISION-MAKING CAPACITY IN GERIATRIC  
PATIENTS
3.1.1	 Participants	with	Alzheimer’s	disease	and	Mild	cognitive	impairment
Participants with Alzheimer’s disease (AD) showed impaired medical decision-making 
capacity (MDC) as assessed by Swedish linguistic instrument for medical decision-making 
(LIMD) and Clinical instrument of medical decision-making capacity (KIMB). Median score 
on KIMB for the group with AD was 13(1-16). Patients with Mild cognitive impairment 
(MCI) showed a marginally higher median score on KIMB, 14(11-19) compared to the AD 
group, but lower compared to the healthy control group, 15(12-19). The differences in score 
between the three groups were statistically significant. Pairwise comparisons showed that 
KIMB score in the group with AD was significantly lower than that in the group with MCI 
and the healthy control group (HCG), while no significant difference was found between 
HCG and MCI.
There was no significant difference in MDC as measured by LIMD among patients with 
AD depending on whether original or adapted vignettes were used. A small significant diffe-
rence was found to depend on trial. Patients showed marginally higher scores on LIMD when 
Kidney disease vignettes were used, as compared to when Hypertension vignettes were used.
One way to illustrate how impairment in MDC manifested in patients with AD, is to go 
back to the scoring instructions for LIMD. The low mean score means that the participants, 
on average, did not even score one point on each of the three assessed aspects of MDC: 
comprehension, evaluation, intelligibility of choice. The scoring protocol stated that one 
point should be given for comprehension if Answers showed some uncertainty regarding if 
information had been correctly understood, specified with the following examples:
• Showed some difficulties in perceiving and understanding the content of the vignette.
• Explained the content only partially.
• Consisted to a large extent of reading parts of the vignette aloud.
• Consisted only occassionally of own wordings.
• Were incomplete.
• Consisted, to some extent, of misunderstanding, erroneuos answers or do not know –
answers. 
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Another way to illustrate MDC among the participants with AD is by examples from the 
transcribed interviews. The examples in Figure 12-15 highlight: 
• The specific problem of distinguishing a hypothetical vignette from the patient’s own 
situation.
• The difference between agreeing to a standard treatment procedure and participating in 
a clinical research was not self-evident.
• Making these kinds of medical decisions was hard.
• Participants occasionally showed preserved capacity to value information.  
The examples are taken from interviews with different participants. Each example contains 
excerpts from the Swedish transcriptions together with an English translation.  
A
Testledare: hade du varit beredd att delta?
Deltagare: ja jag vet faktiskt om ja säger 
osäker i och med att ja har så många saker 
som inte stämmer in riktigt ( )
A
Assessor: would you have been willing to 
participate?
Participant: well I know actually I would 
say I’m not sure because I have a lot of 
things that don’t quite fit ( )
© Liv Thalén, 2019
Figure 12. Transcription from an interview based on one of the hypothetical Hypertension vignettes as 
part of assessment of medical decision-making capacity by Swedish linguistic instrument for medical 
decision-making. The participant showed by the response that he/she had not grasped the idea that the 
vignette concerned a fictitious situation, since the explanation referred to his/her own conditions.
B
Testledare: handlar det om forskning eller 
om behandling?
Deltagare: ja det tror ja definitivt
B
Assessor: does it concern research or 
treatment?
Participant: yes I’m sure of it
© Liv Thalén, 2019
Figure 13. Transcription from an interview based on one of the hypothetical Kidney disease vignettes as 
part of assessment of medical decision-making capacity by Swedish linguistic instrument for medical 
decision-making. The participant showed by the response that he/she had difficulty grasping the diffe-
rence between routine, standard treatment procedures and drug trials in medical research.
C
Testledare: hade du varit beredd att delta?
Deltagare: (4s) förmodligen men ja e inte 
helt säker faktiskt
C
Assessor: would you have been willing to 
participate?
Participant: (4s) probably but actually I’m 
not that sure
© Liv Thalén, 2019
Figure 14. Transcription from an interview based on one of the hypothetical Kidney disease vignettes as 
part of assessment of medical decision-making capacity by Swedish linguistic instrument for medical 
decision-making. The participant highlighted by his/her response that medical decisions, like deciding 
whether to participate in a medical trial or not, can be a complex process.
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D
Testledare: hade du varit beredd att delta?
Deltagare: nej
Testledare: varför hade du inte velat delta?
Deltagare: nej de ja skulle inte utsätta mej 
för dom här grejorna nej de e en  inbyggd 
självbevarelsedrift som mänskan normalt 
har eller en del kanske inte har den men 
därvidlag har jag en skvätt av den
D
Assessor: would you have been willing to 
participate?
Participant: no
Assessor: why would you have declined to 
participate?
Participant: no well I wouldn’t  
expose myself to that stuff no it’s a built-
in survival instinct people normally have 
or maybe some don’t have it but in that 
respect I have a bit
© Liv Thalén, 2019
Figure 15. Transcription from an interview based on one of the hypothetical Hypertension vignettes as 
part assessment of medical decision-making capacity by of in Swedish linguistic instrument for medical 
decision-making. The vignette described a hypothetical drug trial with very high risks and very low 
benefits for participants. The participant showed by the response that in spite of the cognitive impair-
ment that follows with his/her diagnosis of AD, he/she understood the information in the vignette and 
provided a valid reasoning as why to decline participation.
3.1.2	 Clinical	instrument	of	medical	decision-making	capacity
An innovative approach in the validation study of KIMB was to calculate a cut-off score as 
when to pass or fail KIMB. The highest values for sensitivity (75%) and specificity (91%) 
were obtained when ≥14 points (of 19) was set as cut-off score. The high specificity level 
indicated that most healthy adults pass the test, while the somewhat lower sensitivity level 
indicated that also some individuals with presumed cognitive impairment will pass. The 
overall diagnostic accuracy of KIMB was derived from a Receiver operating characteristic 
(ROC) curve. The ROC curve plots the diagnostic properties of a test, using different cut-
off values. The y-axis shows the true positive rate (sensitivity), and the x-axis shows false 
positive rate, calculated as (1 – specificity). The ROC curve and its adherent coordinates of 
the curve are used to find the best cut-off value of a test, which is when both sensitivity and 
specificity level are highest. The Area under the curve is used as an overall measure of a tests 
overall diagnostic validity. The Area under the curve was 0.87 which indicated that KIMB 
was a good test.150 These calculations were made based on the AD and HC groups only. With 
a cut-off value it was possible to calculate prevalence number of suspected impaired MDC. 
Figure 16 shows the ROC curve, including Area under the curve and a null-hypothesis line. 
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Figure 16. ROC curve and Area under the curve based on score on KIMB. Participants with Alzheimer’s 
disease was used as reality check for impaired medical decision-making capacity, and healthy controls 
as reality check for preserved medical decision-making capacity. The null hypothesis is represented by 
the diagonal line.
3.1.3	 Prevalence	 of	 impaired	 medical	 decision-making	 capacity	 among	 
geriatric	patients	with	and	without	dementia
The prevalence of impaired MDC in geriatric patients with AD, MCI and somatically ill, 
geriatric in-patients was calculated using KIMB’s cut-off value. Table 3 shows median, 
minimum and maximum values for each group assessed with KIMB. The healthy control 
group showed highest median value, followed by MCI, AD and the group of somatically ill 
in-patients. The high prevalence of impaired MDC among geriatric patients without known 
cognitive impairment was the main result from study IV. These participants’ mean score on 
KIMB, 9.3±4.9, was as low as that of the AD group in study III: 11.6±3.6 points. A straight-
forward explanation for the high prevalence of impaired MDC could be that these patients, 
despite lacking known cognitive difficulties, nonetheless had at least temporary cognitive 
impairment as measured by MOCA mean score was 21.2(±3.8) out of 30.
Table 3. Score on Clinical instrument of medical decision-making capacity (KIMB) presented as  
median, minimum and maximum values for participants in the Healthy control group, Mild cognitive 
impairment group, Alzheimer’s disease group and the group of geriatric in-patients.
Healthy control 
group  
Mdn(range)
Mild cognitive 
impairment group 
Mdn(range)
Alzheimer’s 
disease group 
Mdn(range)
Somatically ill, 
in-patient group 
Mdn(range)
KIMB 15(12-19) 14(11-19) 13(1-16) 10(0-19)
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Looking into prevalence numbers across studies, a similar pattern appeared. Among partici-
pants with AD, the prevalence of impaired MDC was 91%, and among the in-patients with 
somatic illnesses, the prevalence was 86%. Participants with MCI passed KIMB to a greater 
extent; the prevalence of impaired MDC was 57% in the MCI group. As expected, the healthy 
control group performed best, but 25% did not attain KIMB’s cut-off score. Figure 17 shows 
how many participants failed/passed KIMB in each group. 
 
                                                                                                © Liv Thalén, 2019
Figure 17.  Distribution of how many participants failed and passed Clinical instrument of medical  
decision-making capacity in each group. Among healthy controls, 75% passed the cut-off score (≥14 p), 
while in the Mild cognitive impairment group 43% passed. Only 9% of participants with AD passed, and 
14% of the somatically ill, geriatric in-patients.
3.2 SUBSIDIARY ELEMENTS TO MEDICAL DECISION-MAKING 
CAPACITY 
This section will present and compare results from study II-IV. Interpretations must bear 
in mind that even though LIMD and KIMB were constructed from the same definition of 
MDC, they are two different tests. Furthermore, due to the different characteristics of the 
data, some correlations were made with a parametric test, Pearson’s correlation coefficient 
r, and others with a non-parametric test, Kendall’s tau–b, τ. Numbers for sociodemographic 
factors and cognitive tests are presented in Table 4.
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Table 4. Analyses of correlations to medical decision-making capacity (MDC). MDC was either  
measured with Swedish linguistic instrument for medical decision-making (LIMD) or Clinical  
instrument of medical decision-making capacity (KIMB). The correlations were calculated either using 
Kendall’s tau–b, τ, or Pearson’s correlation coefficient, r. 
Socio-demographic 
factors and tests
Correlations to LIMD 
score
Study II
Correlations to KIMB 
score
 Study III
Correlations to KIMB 
score 
Study IV
Age Non-significant Non-significant Non-significant
Education Non-significant τ = .28*** r = .48**
Overall cognition MMSEA1, r = .50* MOCAA2, τ = .50*** MOCAA2, r =.58**
DLS Reading speedB r = .42* τ = .43*** -
RepetitionC r = .61** τ = .46*** -
InferenceD Non-significant τ = .36*** -
RAVLTE r = .54** τ = .37*** -
Word comprehensionF - - r = .62**
Premorbid overall  
cognitive functionG - - r = .69**
Word sequence  
forwardH - τ = -.20* -
* = significant at r≤.05
**= significant at r≤.01
***= significant at r≤.001
- = not included in the study
A1: Overall cognition as measured by Mini-mental state examination138
A2: Overall cognition as measured by Montreal cognitive assessment140
B: DLS Reading speed (also measures understanding)147
C: Repetition of long sentences from BeSS151
D: Inference from BeSS151
E: Rey auditory verbal learning test152
F: DLS Word comprehension147
G: Irregularly spelled words, a test to estimate premorbid full-scale intelligence quotient153
H: Word sequence forward, months of the year154
Age was not significantly correlated to MDC in any of study II-IV. Educational level, as 
measured by years of formal education, was significantly correlated to MDC as measured 
by KIMB; longer formal education showed a positive, linear relationship to higher score on 
KIMB. However, no significant correlation was found between educational level and LIMD 
score. 
Overall cognition was significantly correlated to MDC in study II-IV, as measured by MMSE 
or MOCA. DLS Reading speed, RAVLT, Repetition of long sentences and Inference were 
used in both study II and III. Higher score on DLS Reading speed was positive, linear and 
significantly correlated to higher score on KIMB (strong correlation) and LIMD (medium 
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correlation). Higher score on both RAVLT and Repetition of long sentences both showed 
strong, positive, linear and significant correlation to KIMB and LIMD. But where Inference 
showed a strong, positive, linear and significant correlation to MDC as measured by KIMB, 
no such correlation was found between Inference and LIMD.
The tests included besides KIMB in study IV assessed potential risk factors for impaired 
MDC. The results showed that smaller receptive vocabulary and lower estimated premorbid 
cognitive function were risk factors to impaired MDC. The correlations for each were strong, 
linear, positive and significant.
3.3 APPROACHES TO FACILITATE MEDICAL DECISION-MAKING
In study I, experiences of communication during discharge meetings were evaluated by 
patients, family members, nurses and social care workers using Visual analogue scales (VAS). 
Counter to the hypothesis, the group where patients had been prepared for their discharge 
meetings using Talking mats (TM) got significantly lower scores on VAS compared to the 
control group. A two-way ANOVA showed a significant interaction effect between how the 
different groups of raters (patients, family members, nurses and social care workers; between 
factor) rated the different statements (within factor). The interaction effect is illustrated in 
study II, Figure 3. The Talking mats group (TMG) also had a fourth statement to rate: I think 
Talking mats has helped communication. The distribution of ratings on this statement was 
large in all groups of raters as shown in Figure 18. 
There was no significant difference in AD patients’ MDC depending on whether original or 
Adapted vignettes were used. A small but significant difference was found to depend on trial; 
the participants showed slightly higher scores on LIMD when Kidney disease vignettes were 
used, compared to when Hypertension vignettes were used.
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Figure 18. Ratings on VAS (0-100 mm) 
to the statement I think Talking mats has 
helped communication given by nur-
ses, social care workers, family members 
and patients present during the discharge 
planning meetings. The patient had been 
prepared using the Talking mats method 
prior to the meeting. In all groups of ra-
ters there was a large range, meaning that 
some individuals did not think Talking mats 
helped the communication at all, while others 
thought it helped a lot.
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4 DISCUSSION
4.1 THE EVER-PRESENT ETHICAL DILEMMA
Three ethical aspects have been highlighted concerning research with geriatric participants: 
1) respect for person, including the span between promoting autonomy and protecting those 
who lack medical decision-making capacity, 2) designing studies which maximize poten-
tial benefit and minimize potential risks and 3) recruiting participants equitably, meaning 
that participants should be representative of the population and appropriate for the research 
questions.155
 
The entitlement to autonomy is enforced globally as well as nationally. All humans are born 
free and equal, and should be free to make their own decisions.156 All potential participants 
should receive adequate information prior to inclusion in order to enable an autonomous 
decision.157 Autonomous decisions within health care and research should be actively 
promoted as far as possible.158 On the other side of an autonomy spectrum, there is need for 
caregivers to protect patients who lack decision-making capacity.159,160 
Impaired medical decision-making capacity, as well as failing participation, have 
potentially negative consequences for a patient. One risk is that an individual who has not 
correctly apprehended information given, makes a decision based on incomplete or even 
incorrect premises. Patients with Alzheimer’s disease are at hazard of underestimating risks in 
medical research.161 Another problem concerns if a patient is not asked to participate in a study, 
because of presumed incompetence to give informed consent. Possible explanations might 
be that caregivers are unsure of how to assess medical decision-making capacity and lack 
knowledge of current policies.162 Existing interventions to protect an individual who lacks 
decision-making capacity are, for example, advance directives, a proxy as a decision-maker 
or a legally appointed administrator or surrogate decision-maker.158-160,163-165
A high level of medical decision-making capacity is required to give informed consent to 
a clinical trial. Prior to inclusion in medical research, it is important to correctly identify 
participants at risk of not understanding information given.166 Even cognitively intact patients 
and healthy controls may struggle with this type of decision. The written information, likely 
containing technical terms, requires the potential participant to have a high reading level to 
correctly interpret and apply the information.
The crux – ensuring that each participant has understood what the research is about – has 
been present in this doctoral project from start to finish. To indicate that the participants 
have given their truly informed consent to a study, when the study’s results show that a 
majority of the participants are at immediate risk of impaired medical decision-making 
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capacity, constitutes a dilemma. All studies included were approved of the Regional ethical 
committee, Stockholm, and thus followed the legal framework concerning adults with impaired 
decisional capacity: 
• The research questions could not have been answered using other, decisionally 
competent, participants.
• The research was expected to yield results that would benefit either the patients 
themselves, or others with the same conditions.
• The research entailed an insignificant risk of injury and an insignificant risk of 
discomfort.
• Inclusion to the study was done in consultation with the next of kin of patients with 
dementia.
• The person carrying out the parts of the studies that involved interactions with partici-
pants was continously on the lookout for any signs that they did not want to participate.
4.2 DISCUSSION OF METHODOLOGY
4.2.1	 Sample	and	design
Study I has most potential weaknesses regarding design and results. The intention to let par-
ticipants evaluate aspects of communication on VAS in study IV was valid since patients’ 
experiences are an important aspect of communication and participation. Comparison 
between groups showed higher ratings for communication quality in the control group than 
in the Talking mats group. Therefore, it would have been interesting to objectively examine 
communication and participation during the meetings. An objective analysis based on video 
recording would have been needed to meet that end. Furthermore, there was no check to see 
if the Talking mat that was used to prepare the participant was also used during the discharge 
meeting.
4.2.2	 Data	analysis	and	material
Aspects of the vignette in Clinical instrument of medical decision-making capacity (KIMB) 
were hard to comprehend and appreciate regardless of cognitive status, as shown by the 
relatively low median score in the healthy control group. During the construction and initial 
testing of KIMB, healthy individuals got higher scores on KIMB than the healthy individuals 
examined during study III. An explanation might be found in the different samples. Most of 
the healthy individuals approached in the construction of KIMB either worked in health care 
or were speech and language pathology students. It is conceivable that being familiar with 
technical terms and research procedures could enhance the understanding of a person being 
asked for consent/assent to participate in clinical trials.
An innovative feature of KIMB was to present a cut-off value, which existing tests that 
assess medical decision-making capacity using the vignette method do not (MacCAT-CR,167 
UBACC62 and LIMD24). A cut-off indicates that any score below this value should 
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prompt one or more interventions, for example further assessment, support in medical 
decision-making processes and addressing a surrogate decision-maker. Lack of a cut-off 
value may make it more difficult to know how to interpret the result. However, the lack of a 
cut-off may encourage the assessor to make a holistic evaluation, for example using his/her 
own clinical judgment.54 
4.3 DISCUSSION OF INTEGRATED RESULTS
4.3.1	 High	 prevalence	 of	 impaired	 medical	 decision-making	 capacity	 in	 
geriatric	patients	with	and	without	dementia
An unexpected similarity between the studies in this thesis, was that in-ward patients parti-
cipating in study IV with an explicit exclusion criterion regarding cognitive impairment and 
acute confusion, showed median KIMB score as low as the median score among patients 
with Alzheimer’s disease. In-ward geriatric patients as a group may be at risk of impaired 
medical decision-making capacity regardless of whether they are affected by dementia or 
not; the prevalence number of impaired medical decision-making capacity among somatic 
in-ward patients was very high, 86%. In previous studies, in-patients without dementia have 
had reported prevalence numbers between 30-50% of impaired medical decision-making 
capacity as assessed by MacCAT-T.52,92,93,168 The in-patients’ results gave a snapshot of their 
medical decision-making capacity. Their capacity may have improved after recovery and 
discharge. Investigating the prevalence of impaired capacity among other groups of in- 
patients, but also geriatric out-patients without cognitive impairment would be of interest in 
future research. 
Explanations for the impaired medical decision-making capacity may be found within 
investigated risk factors. Higher age has been shown in other studies to correlate with lower 
medical decision-making capacity, although no such correlation was seen in this thesis. Older 
individuals tend to have shorter formal education, which was correlated to lower scores on 
medical decision-making capacity within this thesis and elsewhere.110,131 Other factors not yet 
addressed need further investigation. Pain of a magnitude that it was obvious that pain affec-
ted a patient’s general condition was an exclusion criterion. However, no measure addressed 
pain. Some participants probably experienced pain or discomfort to some degree. Another 
factor of interest is how tired the patient felt when participating in the study. 
4.3.2	 Applicability	of	Clinical	instrument	of	medical	decision-making	capacity 
KIMB is primarily intended to be applied to assess a potential participant’s medical 
decision-making capacity prior to inclusion in a clinical trial. Decisions based on a 
hypothetical vignette may not accurately reflect a person’s capacity regarding information 
for an actual trial.58 An advantage, however, is that using a test based on a hypothetical vignette 
enables researchers to compare scores between settings and diagnoses.29 A disadvantage 
is that KIMB requires reading skills, but the test can be completed quickly and is easily 
corrected.
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A theoretical perspective is valuable when discussing applicability of KIMB. In order to 
have a well-functioning medical decision-making capacity, all components should be 
present. If so, as soon as an individual scores lower than maximum, further assessment or 
other actions would be needed in the medical decision-making process. The fact that seven 
healthy controls did not pass the cut-off score, and that only two got 19/19, supports previous 
studies that also cognitively intact individuals may imperceptibly struggle to give truly infor-
med consent.131,132,169,170 The difficulties that possibly face even healthy controls may explain 
why their KIMB scores did not differ from those of participants with Mild cognitive impair-
ment. Another explanation could be that KIMB does not capture subtle variations in medical 
decision-making capacity.
There are several reasons why a specific assessment of medical decision-making 
capacity is needed, even though scores typically correlate to screening of overall cognitive 
function. MMSE underestimated impaired medical decision-making capacity among the elderly 
individuals in assisted living facilities.168 A diagnosis of dementia or a score on a screen-
ing test cannot be used on individual level to draw conclusions regarding medical decision- 
making capacity. KIMB gives a standardized measure and indicates which aspects an 
individual struggles with. The specific deficiencies detected can indicate where further 
actions are needed. The test result can be used to explain strengths and difficulties to all parties 
involved in the decision-making process, like patient and next of kin. However, it may be 
ethically problematic to test a person before he/she has consented to participate in a study.
Using KIMB in study IV gave a first glimpse of its applicability in a clinical setting. In view 
of the discrepancy noted between clinicians when subjectively judging a patient’s medical 
decision-making capacity,171  it could be argued that it could be better to use KIMB than 
to rely solely on subjective judgment, even though it is intended for use in the context of 
informed consent in clinical trials. But of course, this would be up to each clinician to decide, 
as well as how to act as depending on a patient’s score. 
4.3.3	 Communication:	 difficulties	 and	 opportunities	 in	 medical	 decision- 
making	processes
The Adapted vignettes had a linguistic construction that was in some but not all ways simpler 
than in the original vignettes as analyzed by SVIT. In order to keep ecological validity, it was 
important that relevant information regarding risks and treatment was kept in the Adapted 
vignettes. However, LIMD scores did not increase. One explanation could be that the partici-
pants were too affected by cognitive impairment to benefit from this kind of support.
The results in study II have important implications; even though the information was 
specifically adapted to be more easily comprehended by patients with AD, these individuals 
still exhibited extensive impairments in medical decision-making capacity. While the use of 
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“plain language” has been suggested as way to increase participants’ understanding of infor-
mation given prior to inclusion in a clinical trial,172 the results of study II suggest that this is 
not a valid strategy for geriatric patients with dementia. 
Several interpersonal factors were found to be related to medical decision-making capaci-
ty within the studies: age and formal education have already been mentioned. In addition, 
positive correlations were found to overall cognitive function. Since medical decision- 
making capacity is a multi-faceted cognitive function, correlations to screening tests of 
overall cognitive function could be expected. Indeed, overall cognition can be the 
most well-documented predictor for medical decision-making capacity.25 Positi-
ve, significant correlations to DLS Reading speed,147 RAVLT152 and Repetition of long 
sentences147 followed the same pattern as previously published correlations to LIMD.32 
A compilation of interpersonal factors affecting medical decision-making capacity, based on 
integrated results, is found in Figure 19. 
 
 © Liv Thalén, 2019
Figure 19. Interpersonal factors with relationships to patients’ medical decision-making capacity based 
on integrated results (inclusion/exclusion criteria in italics).
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5 A PROPOSED MODEL TO STANDARDIZE INFORMED 
CONSENT PROCEDURES
Medical decision-making processes can be difficult to participate in for in-ward geriatric 
patients regardless of whether a neurodegenerative process is present or not. Medical 
decision-making capacity is also affected early in Alzheimer’s disease. The ability to give 
informed consent cannot be taken for granted in the geriatric patient group. Formal care- 
givers have the responsibility to support patients to participate as best they are able in their 
own medical decision-making. 
Researchers frequently ask patients to consent to participate in a study, but a standardized 
method which emphasizes each individual’s right to understand information and make an 
autonomous decision is lacking. Figure 20 presents a suggested standardized procedure for 
inclusion to medical research. The aim of the flowchart is to promote best possible partici-
pation in the decision-making and most clearly discern the free will of each geriatric patient, 
based on a communicative approach. A Swedish version is found in Figure 21. In future 
studies, it would be of interest to examine if this flow-chart can help researchers exercise their 
responsibilities during medical decision-making processes, and what consequences that has 
for geriatric participants and their next of kin.
 
 
© Liv Thalén, 2019
Figure 20. Suggested standardized process for researchers when asking geriatric patients for informed 
consent to participate in a clinical trial. 
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